Publicacións nas que colabora con Julián de la Torre Cisneros (36)

2022

  1. Current Positioning against Severe Infections Due to Klebsiella pneumoniae in Hospitalized Adults

    Antibiotics, Vol. 11, Núm. 9

  2. Recommendations for prevention of infection in systemic autoimmune rheumatic diseases

    Reumatologia Clinica, Vol. 18, Núm. 6, pp. 317-330

2020

  1. Genomic analysis of 40 prophages located in the genomes of 16 carbapenemase-producing clinical strains of Klebsiella pneumoniae

    Microbial Genomics, Vol. 6, Núm. 5, pp. 1-18

  2. In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens

    Scientific Reports, Vol. 10, Núm. 1

2018

  1. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals

    Clinical Microbiology and Infection, Vol. 24, Núm. 10, pp. 1070-1076

  2. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

  3. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations

    Transplantation Reviews, Vol. 32, Núm. 1, pp. 36-57

2017

  1. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae

    The Journal of antimicrobial chemotherapy, Vol. 72, Núm. 3, pp. 906-913

  2. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

    The Lancet Infectious Diseases, Vol. 17, Núm. 7, pp. 726-734

  3. Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort

    Clinical Infectious Diseases, Vol. 65, Núm. 10, pp. 1615-1623

  4. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study

    International Journal of Antimicrobial Agents, Vol. 50, Núm. 5, pp. 664-672

  5. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: Discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 5, pp. 1478-1487

2016

  1. A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 7, pp. 4159-4169

  2. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: A multinational pre-registered cohort study

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 6, pp. 1672-1680

  3. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

  4. Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study

    American Journal of Transplantation, Vol. 16, Núm. 2, pp. 679-687

2015

  1. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey

    Clinical Microbiology and Infection, Vol. 21, Núm. 6, pp. 604.e1-604.e9

  2. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  3. Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: A retrospective multicenter case-control study

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 89-95

  4. Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: Safety analysis of a multicenter randomized trial

    Clinical Infectious Diseases, Vol. 60, Núm. 11, pp. 1642-1649